Hwa-Jin Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hwa-Jin Park has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Hak-Chul Hyun
Department of Biomedical Pharmacology, Korea Ginseng and Tobacco Research Institute
1 shared publicationHan-Jae Shin
Department of Biomedical Pharmacology, Korea Ginseng and Tobacco Research Institute
1 shared publicationHye-Seon Ham
Department of Biomedical Laboratory Science, College of Biomedical Science and Engineering, Inje University
1 shared publicationHyun-Jeong Cho
Department of Biomedical Laboratory Science, College of Biomedical Science and Engineering, Inje University
1 shared publicationKi-Hyun Park
Department of Biomedical Pharmacology, Korea Ginseng and Tobacco Research Institute, Taejon
1 shared publicationWoong-Tak Jun
Department of Biomedical Laboratory Science, College of Biomedical Science and Engineering, Inje University
1 shared publication
Latest Publications
- Open Access
- 1 January 2002
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 25 (4) , 457-460
Possible Role of Ginsenoside Rb1 on Regulation of Rat Liver Triglycerides.
We have studied the effects of ginsenoside Rb1 (GRb1) on the change in lipid contents in rat liver. When GRb1 was administered intraperitoneally to rats, liver microsomal cytochrome P-450 content and NADPH-cytochrome P-450 reductase activity were lower than those in control rats. The contents of triglyceride (TG) and cholesterol were decreased, but those of total phospholipid, phosphatidylcholine, and phosphatidylethanolamine were increased in the GRb1-treated group compared with controls. These results indicate that GRb1 might be involved in lipid metabolism by regulating the activity of microsomal cytochrome P-450 monooxygenase. Although liver TG levels were reduced by GRb1, the levels of TG and β-lipoprotein in serum from the GRb1-treated group did not change as compared with those in controls. Thus we suggest that the decrease in liver TG levels with GRb1-treatment is not associated with the secretion of TG-rich very low-density lipoprotein. Furthermore, the level of cAMP was also significantly increased in the GRb1-treated group as compared with that in controls. Additionally, the cAMP level was more markedly increased as compared with that in the GRb1-treated group or control group when GRb1 was exogenously added to the reaction system for measuring cAMP production in homogenates from control group liver. Accordingly, these results demonstrate that GRb1 might lower TG levels via cAMP-production in the liver, and GRb1 might be an interesting candidate to for a modulator of cAMP-mediated effects, especially within the liver steatosis system.
- 1 January 2002
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 25 (4) , 457-460
Open AccessPossible Role of Ginsenoside Rb1 on Regulation of Rat Liver Triglycerides.
We have studied the effects of ginsenoside Rb1 (GRb1) on the change in lipid contents in rat liver. When GRb1 was administered intraperitoneally to rats, liver microsomal cytochrome P-450 content and NADPH-cytochrome P-450 reductase activity were lower than those in control rats. The contents of triglyceride (TG) and cholesterol were decreased, but those of total phospholipid, phosphatidylcholine, and phosphatidylethanolamine were increased in the GRb1-treated group compared with controls. These results indicate that GRb1 might be involved in lipid metabolism by regulating the activity of microsomal cytochrome P-450 monooxygenase. Although liver TG levels were reduced by GRb1, the levels of TG and β-lipoprotein in serum from the GRb1-treated group did not change as compared with those in controls. Thus we suggest that the decrease in liver TG levels with GRb1-treatment is not associated with the secretion of TG-rich very low-density lipoprotein. Furthermore, the level of cAMP was also significantly increased in the GRb1-treated group as compared with that in controls. Additionally, the cAMP level was more markedly increased as compared with that in the GRb1-treated group or control group when GRb1 was exogenously added to the reaction system for measuring cAMP production in homogenates from control group liver. Accordingly, these results demonstrate that GRb1 might lower TG levels via cAMP-production in the liver, and GRb1 might be an interesting candidate to for a modulator of cAMP-mediated effects, especially within the liver steatosis system.